Correlation between TSH receptor antibody assays and clinical manifestations of graves' orbitopathy

Sun Young Jang, Dong Yeob Shin, Eun Jig Lee, Young Joon Choi, Sang Yeul Lee, Jin Sook Yoon

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: To investigate an association between the levels of serum thyroid-stimulating hormone (TSH)-receptor autoantibodies (TRAbs) and Graves' orbitopathy (GO) activity/severity scores, and compare the performance of three different TRAb assays in assessing the clinical manifestations of GO. Materials and Methods: Cross-sectional study. Medical records of 155 patients diagnosed with GO between January 2008 and December 2010 were reviewed. GO activity was assessed by clinical activity score (CAS) and severity graded with the modified NOSPECS score by a single observer. Serum TRAb was measured by three different methods: 1st generation thyrotropin-binding inhibitor immunoglobulin (TBII) assay (TRAb1st); 3rd generation TBII assay (TRAb3rd); and biological quantitative assay of thyroid-stimulating immunoglobulin (TSI) using Mc4-CHO cells (Mc4-CHO TSI assay). Results were correlated with scores of activity/severity of thyroid eye disease. Results: All three assays (TRAb1st, TRAb3rd, and Mc4-CHO TSI) yielded results that were significantly positively correlated with CAS (β=0.21, 0.21, and 0.46, respectively; p<0.05) and proptosis (β=0.38, 0.34, and 0.33, respectively; p<0.05). Mc4-CHO TSI bioassay results were significantly positively correlated with all GO severity indices (soft tissue involvement, proptosis, extraocular muscle involvement, and total eye score; β=0.31, 0.33, 0.25, and 0.39, respectively; p<0.05). Conclusion: Mc4-CHO TSI bioassay was superior over the two TBIIs in assessing active inflammation and muscle restriction due to GO, whereas TBII assay would be sufficient for evaluation of patients with proptosis.

Original languageEnglish
Pages (from-to)1033-1039
Number of pages7
JournalYonsei medical journal
Volume54
Issue number4
DOIs
Publication statusPublished - 2013 Jul 1

Fingerprint

Thyroid-Stimulating Immunoglobulins
Thyrotropin Receptors
Exophthalmos
Thyrotropin
Antibodies
Biological Assay
Autoantibodies
Immunoglobulins
Oculomotor Muscles
Eye Diseases
CHO Cells
Thyroid Diseases
Serum
Medical Records
Cross-Sectional Studies
Inflammation
Muscles

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Jang, Sun Young ; Shin, Dong Yeob ; Lee, Eun Jig ; Choi, Young Joon ; Lee, Sang Yeul ; Yoon, Jin Sook. / Correlation between TSH receptor antibody assays and clinical manifestations of graves' orbitopathy. In: Yonsei medical journal. 2013 ; Vol. 54, No. 4. pp. 1033-1039.
@article{f6cabb9e722c4147bd9c83eda429b32a,
title = "Correlation between TSH receptor antibody assays and clinical manifestations of graves' orbitopathy",
abstract = "Purpose: To investigate an association between the levels of serum thyroid-stimulating hormone (TSH)-receptor autoantibodies (TRAbs) and Graves' orbitopathy (GO) activity/severity scores, and compare the performance of three different TRAb assays in assessing the clinical manifestations of GO. Materials and Methods: Cross-sectional study. Medical records of 155 patients diagnosed with GO between January 2008 and December 2010 were reviewed. GO activity was assessed by clinical activity score (CAS) and severity graded with the modified NOSPECS score by a single observer. Serum TRAb was measured by three different methods: 1st generation thyrotropin-binding inhibitor immunoglobulin (TBII) assay (TRAb1st); 3rd generation TBII assay (TRAb3rd); and biological quantitative assay of thyroid-stimulating immunoglobulin (TSI) using Mc4-CHO cells (Mc4-CHO TSI assay). Results were correlated with scores of activity/severity of thyroid eye disease. Results: All three assays (TRAb1st, TRAb3rd, and Mc4-CHO TSI) yielded results that were significantly positively correlated with CAS (β=0.21, 0.21, and 0.46, respectively; p<0.05) and proptosis (β=0.38, 0.34, and 0.33, respectively; p<0.05). Mc4-CHO TSI bioassay results were significantly positively correlated with all GO severity indices (soft tissue involvement, proptosis, extraocular muscle involvement, and total eye score; β=0.31, 0.33, 0.25, and 0.39, respectively; p<0.05). Conclusion: Mc4-CHO TSI bioassay was superior over the two TBIIs in assessing active inflammation and muscle restriction due to GO, whereas TBII assay would be sufficient for evaluation of patients with proptosis.",
author = "Jang, {Sun Young} and Shin, {Dong Yeob} and Lee, {Eun Jig} and Choi, {Young Joon} and Lee, {Sang Yeul} and Yoon, {Jin Sook}",
year = "2013",
month = "7",
day = "1",
doi = "10.3349/ymj.2013.54.4.1033",
language = "English",
volume = "54",
pages = "1033--1039",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "4",

}

Correlation between TSH receptor antibody assays and clinical manifestations of graves' orbitopathy. / Jang, Sun Young; Shin, Dong Yeob; Lee, Eun Jig; Choi, Young Joon; Lee, Sang Yeul; Yoon, Jin Sook.

In: Yonsei medical journal, Vol. 54, No. 4, 01.07.2013, p. 1033-1039.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Correlation between TSH receptor antibody assays and clinical manifestations of graves' orbitopathy

AU - Jang, Sun Young

AU - Shin, Dong Yeob

AU - Lee, Eun Jig

AU - Choi, Young Joon

AU - Lee, Sang Yeul

AU - Yoon, Jin Sook

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Purpose: To investigate an association between the levels of serum thyroid-stimulating hormone (TSH)-receptor autoantibodies (TRAbs) and Graves' orbitopathy (GO) activity/severity scores, and compare the performance of three different TRAb assays in assessing the clinical manifestations of GO. Materials and Methods: Cross-sectional study. Medical records of 155 patients diagnosed with GO between January 2008 and December 2010 were reviewed. GO activity was assessed by clinical activity score (CAS) and severity graded with the modified NOSPECS score by a single observer. Serum TRAb was measured by three different methods: 1st generation thyrotropin-binding inhibitor immunoglobulin (TBII) assay (TRAb1st); 3rd generation TBII assay (TRAb3rd); and biological quantitative assay of thyroid-stimulating immunoglobulin (TSI) using Mc4-CHO cells (Mc4-CHO TSI assay). Results were correlated with scores of activity/severity of thyroid eye disease. Results: All three assays (TRAb1st, TRAb3rd, and Mc4-CHO TSI) yielded results that were significantly positively correlated with CAS (β=0.21, 0.21, and 0.46, respectively; p<0.05) and proptosis (β=0.38, 0.34, and 0.33, respectively; p<0.05). Mc4-CHO TSI bioassay results were significantly positively correlated with all GO severity indices (soft tissue involvement, proptosis, extraocular muscle involvement, and total eye score; β=0.31, 0.33, 0.25, and 0.39, respectively; p<0.05). Conclusion: Mc4-CHO TSI bioassay was superior over the two TBIIs in assessing active inflammation and muscle restriction due to GO, whereas TBII assay would be sufficient for evaluation of patients with proptosis.

AB - Purpose: To investigate an association between the levels of serum thyroid-stimulating hormone (TSH)-receptor autoantibodies (TRAbs) and Graves' orbitopathy (GO) activity/severity scores, and compare the performance of three different TRAb assays in assessing the clinical manifestations of GO. Materials and Methods: Cross-sectional study. Medical records of 155 patients diagnosed with GO between January 2008 and December 2010 were reviewed. GO activity was assessed by clinical activity score (CAS) and severity graded with the modified NOSPECS score by a single observer. Serum TRAb was measured by three different methods: 1st generation thyrotropin-binding inhibitor immunoglobulin (TBII) assay (TRAb1st); 3rd generation TBII assay (TRAb3rd); and biological quantitative assay of thyroid-stimulating immunoglobulin (TSI) using Mc4-CHO cells (Mc4-CHO TSI assay). Results were correlated with scores of activity/severity of thyroid eye disease. Results: All three assays (TRAb1st, TRAb3rd, and Mc4-CHO TSI) yielded results that were significantly positively correlated with CAS (β=0.21, 0.21, and 0.46, respectively; p<0.05) and proptosis (β=0.38, 0.34, and 0.33, respectively; p<0.05). Mc4-CHO TSI bioassay results were significantly positively correlated with all GO severity indices (soft tissue involvement, proptosis, extraocular muscle involvement, and total eye score; β=0.31, 0.33, 0.25, and 0.39, respectively; p<0.05). Conclusion: Mc4-CHO TSI bioassay was superior over the two TBIIs in assessing active inflammation and muscle restriction due to GO, whereas TBII assay would be sufficient for evaluation of patients with proptosis.

UR - http://www.scopus.com/inward/record.url?scp=84878253125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878253125&partnerID=8YFLogxK

U2 - 10.3349/ymj.2013.54.4.1033

DO - 10.3349/ymj.2013.54.4.1033

M3 - Article

C2 - 23709442

AN - SCOPUS:84878253125

VL - 54

SP - 1033

EP - 1039

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 4

ER -